T-DXd in the DB11 NACT Space: Is De-escalation in adjuvant setting Possible by Maximizing pCR?

Four Cycles of Neoadjuvant T-DXd — Higher pCR rates and a favorable safety profile suggest the potential for adjuvant de-escalation. The DESTINY-Breast11 data may redefine how we minimize toxicity while balancing efficacy and treatment burden in high-risk, HER2+ early stage breast cancer.